Cost effectiveness of bone density measurements

Journal of the British Menopause Society

Volumn 7, Issue 3, 2001, Pages 130-135

  Brown, M A ^a   Bradlow, J ^b   Gray, A M ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b Oxfordshire Dept of Public Health   (United Kingdom)

^c Economics Research Centre   (United Kingdom)

Author keywords

Alendronate; Cost benefit analysis; Densitometry; Hormone replacement therapy; Osteoporosis

Indexed keywords

ALENDRONIC ACID; HORMONE;

ADULT; AGED; ARTICLE; BONE DENSITY; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DENSITOMETRY; DRUG COST; DRUG EFFICACY; FEMALE; FRACTURE; HEALTH CARE COST; HEALTH PROGRAM; HORMONE SUBSTITUTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MASS SCREENING; OSTEOPOROSIS; OUTCOMES RESEARCH; POPULATION RESEARCH; POPULATION RISK; QUALITY ADJUSTED LIFE YEAR;

EID: 0034805451     PISSN: 13621807     EISSN: None     Source Type: Journal    
DOI: 10.1258/136218001100321290     Document Type: Article

References (22)

1. The cost of treating osteoporotic fractures in the United Kingdom female population
2. Department of Health shoots itself in the hip. Why the report of the Advisory Group on Osteoporosis undermines evidence based purchasing
3. Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease
4. The economics of fracture prevention
5. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen
6. Hip fracture and the use of estrogens in postmenopausal women
7. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group
8. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group
9. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group
10. Health-related quality of life in economic evaluations for osteoporosis: Whose values should we use?
11. Quality of life related to fear of falling and hip fracture in older women: A time trade off study
12. Population-based study of survival after osteoporotic fractures
13. The effect of risedronate on the risk of hip fracture in elderly women
14. Predictors of fractures in elderly women
15. How hip and whole-body bone mineral density predict hip fracture in elderly women: The EPIDOS Prospective Study
16. Cost effectiveness of screening perimenopausal white women for osteoporosis: Bone densitometry and hormone replacement therapy
17. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics
18. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures
19. Mortality after all major types of osteoporotic fracture in men and women: An observational study
20. Identification of women with reduced bone density at the lumbar spine and femoral neck using BMD at the os calcis
21. Cost effectiveness analysis of BMD referral for DXA using ultrasound as a selective pre-screen in a group of women with low trauma Colle's fractures